The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of single ascending oral doses(SAD) of PG-033 by directly comparing it with placebo. Meanwhile, the impact of a high-fat meal on the pharmacokinetics of PG-033 will also be evaluated. The research will also explore the potential metabolites and metabolic pathways of PG-033 within the human body，as well as investigate the effect of PG-033 on the QTc interval.
1. Read, understood, and signed an ICF before any investigational procedure(s) are performed.
1. Participants with abnormal electrocardiogram results during screening (e.g., QT/QTcF > 440 ms, PR interval > 200 ms, QRS complex duration > 100 ms, clinically significant abnormalities of the P wave, clinically significant changes in the ST-T wave, etc.).
Parallel
PG-033
DrugOral tablets (2mg， 10mg)
PG-033 placebo comparator
DrugOral tablets (2 mg, 10 mg) (matching corresponding study medication)
Safety and tolerability of PG-033 tablets
Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
Pharmacokinetics parameter: Cmax
Maximum Observed Plasma concentration (Cmax)
Pharmacokinetics Parameter:Tmax
Time at which the maximum plasma concentration (Cmax) occurs
Pharmacokinetics parameter: AUC0-t
Area under the plasma concentration-time curve from dosing (time zero） to the time of the last measured concentration
Pharmacokinetics parameter: AUC0-∞
Area Under the Plasma Concentration Versus Time Curve from Zero Extrapolated to Infinity (AUC0-∞）
Click on the lead sponsor to view all of their trials.
